ALNY Alnylam Pharmaceuticals Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALNY
  4. Earnings
Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 98

EPS in 2026 (TTM): $20.38

Last Report Period Date: Sep 30, 2026

According to the most recent financial data from September 2026, the EPS for the trailing twelve months is $20.38. Alnylam Pharmaceuticals's EPS for 2025 amounted to $2.39, marking an increase from -$2.18 in 2024. During the quarterly period ending on Sep 30, 2026, ALNY's EPS stood at $16.19.

ALNY earnings history

Historical annual and quarterly earnings per share (EPS) data for Alnylam Pharmaceuticals
EPS (TTM)
$20.38
EPS Growth YoY (Quarterly)
626%
EPS (Quarterly)
$16.19
EPS Growth (Quarterly)
1,216.3%

Alnylam Pharmaceuticals had an annual EPS of $2.39, indicating an increase of 209.6% from -$2.18 in 2024. The quarterly per-share earnings for the period ending Sep 30, 2026, was $16.19, indicating a 626% increase from the same quarter last year. ALNY's 12-month EPS stands at $20.38 as of September 2026. Alnylam Pharmaceuticals's annual EPS in 2024 stood at -$2.18, a 38.1% increase year-over-year.

ALNY EPS vs price chart

ALNY EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
626%
EPS growth YoY
209.6%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

During the last 12 months, Alnylam Pharmaceuticals has seen an EPS growth of 626% (YoY, quarterly).

ALNY Earnings Waterfall

Breakdown of revenue, profit and net income for Alnylam Pharmaceuticals

ALNY Earnings vs Peers

What are the earnings of ALNY compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
ALNY Alnylam Pharmaceuticals Inc 8.1 209.6% N/A N/A
REGN Regeneron Pharmaceuticals Inc 20.32 5.3% 2.1% 5.7%
NVS Novartis AG 30.57 21.8% 31.2% 15.2%
TEVA Teva- Pharmaceutical Industries Ltd 98.89 184.8% N/A N/A
SRPT Sarepta Therapeutics Inc 229.57 -388.7% N/A N/A
ARWR Arrowhead Pharmaceuticals Inc N/A 99.8% N/A N/A
OPK Opko Health Inc N/A -275% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.